These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 37935198

  • 1. The proteasome component PSMD14 drives myelomagenesis through a histone deubiquitinase activity.
    He L, Yu C, Qin S, Zheng E, Liu X, Liu Y, Yu S, Liu Y, Dou X, Shang Z, Wang Y, Wang Y, Zhou X, Liu B, Zhong Y, Liu Z, Lu J, Sun L.
    Mol Cell; 2023 Nov 16; 83(22):4000-4016.e6. PubMed ID: 37935198
    [Abstract] [Full Text] [Related]

  • 2. PSMD14 Targeting Triggers Paraptosis in Breast Cancer Cells by Inducing Proteasome Inhibition and Ca2+ Imbalance.
    Lee HJ, Lee DM, Seo MJ, Kang HC, Kwon SK, Choi KS.
    Int J Mol Sci; 2022 Feb 28; 23(5):. PubMed ID: 35269789
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Deubiquitinase PSMD14 enhances hepatocellular carcinoma growth and metastasis by stabilizing GRB2.
    Lv J, Zhang S, Wu H, Lu J, Lu Y, Wang F, Zhao W, Zhan P, Lu J, Fang Q, Xie C, Yin Z.
    Cancer Lett; 2020 Jan 28; 469():22-34. PubMed ID: 31634528
    [Abstract] [Full Text] [Related]

  • 9. Novel insights into the non-canonical roles of PSMD14/POH1/Rpn11 in proteostasis and in the modulation of cancer progression.
    Bustamante HA, Albornoz N, Morselli E, Soza A, Burgos PV.
    Cell Signal; 2023 Jan 28; 101():110490. PubMed ID: 36241058
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The deubiquitinating enzyme PSMD14 facilitates tumor growth and chemoresistance through stabilizing the ALK2 receptor in the initiation of BMP6 signaling pathway.
    Seo D, Jung SM, Park JS, Lee J, Ha J, Kim M, Park SH.
    EBioMedicine; 2019 Nov 28; 49():55-71. PubMed ID: 31685442
    [Abstract] [Full Text] [Related]

  • 12. The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma.
    Vdovin A, Jelinek T, Zihala D, Sevcikova T, Durech M, Sahinbegovic H, Snaurova R, Radhakrishnan D, Turi M, Chyra Z, Popkova T, Venglar O, Hrdinka M, Hajek R, Simicek M.
    Nat Commun; 2022 Nov 10; 13(1):6820. PubMed ID: 36357400
    [Abstract] [Full Text] [Related]

  • 13. Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma.
    Jiang H, Wang Y, Wang J, Wang Y, Wang S, He E, Guo J, Xie Y, Wang J, Li X, Peng Z, Wang M, Hou J, Liu Z.
    Clin Transl Med; 2022 Apr 10; 12(4):e744. PubMed ID: 35389552
    [Abstract] [Full Text] [Related]

  • 14. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
    Xie Y, Liu J, Jiang H, Wang J, Li X, Wang J, Zhu S, Guo J, Li T, Zhong Y, Zhang Q, Liu Z.
    Oncogene; 2020 Jan 10; 39(4):922-934. PubMed ID: 31576013
    [Abstract] [Full Text] [Related]

  • 15. Deubiquitinating enzyme PSMD14 promotes tumor metastasis through stabilizing SNAIL in human esophageal squamous cell carcinoma.
    Zhu R, Liu Y, Zhou H, Li L, Li Y, Ding F, Cao X, Liu Z.
    Cancer Lett; 2018 Apr 01; 418():125-134. PubMed ID: 29331416
    [Abstract] [Full Text] [Related]

  • 16. Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence.
    Byrne A, McLaren RP, Mason P, Chai L, Dufault MR, Huang Y, Liang B, Gans JD, Zhang M, Carter K, Gladysheva TB, Teicher BA, Biemann HP, Booker M, Goldberg MA, Klinger KW, Lillie J, Madden SL, Jiang Y.
    Exp Cell Res; 2010 Jan 15; 316(2):258-71. PubMed ID: 19732767
    [Abstract] [Full Text] [Related]

  • 17. Deubiquitinating enzyme PSMD14 facilitates gastric carcinogenesis through stabilizing PTBP1.
    Li J, Li Y, Xu F, Sun B, Yang L, Wang H.
    Exp Cell Res; 2022 Jun 15; 415(2):113148. PubMed ID: 35405117
    [Abstract] [Full Text] [Related]

  • 18. Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness.
    Jing C, Duan Y, Zhou M, Yue K, Zhuo S, Li X, Liu D, Ye B, Lai Q, Li L, Yao X, Wei H, Zhang W, Wu Y, Wang X.
    Theranostics; 2021 Jun 15; 11(6):2655-2669. PubMed ID: 33456565
    [Abstract] [Full Text] [Related]

  • 19. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
    Thangavadivel S, Zelle-Rieser C, Olivier A, Postert B, Untergasser G, Kern J, Brunner A, Gunsilius E, Biedermann R, Hajek R, Pour L, Willenbacher W, Greil R, Jöhrer K.
    Oncotarget; 2016 Nov 29; 7(48):78605-78618. PubMed ID: 27732933
    [Abstract] [Full Text] [Related]

  • 20. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
    Yerlikaya A, Okur E, Baykal AT, Acılan C, Boyacı I, Ulukaya E.
    J Proteomics; 2015 Jan 15; 113():315-25. PubMed ID: 25305590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.